Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease

Jin Hwa Lee, Michael H. Cho, Craig P. Hersh, Merry Lynn N McDonald, James D. Crapo, Per S. Bakke, Amund Gulsvik, Alejandro P. Comellas, Christine H. Wendt, David A. Lomas, Victor Kim, Edwin K. Silverman, Elizabeth A. Regan, Stephanie Bratschie, Rochelle Lantz, Sandra Melanson, Terri Beaty, Russell P. Bowler, Jeffrey L. Curtis, Douglas EverettMei Lan K Han, John E. Hokanson, E. Rand Sutherland, Eugene R. Bleecker, Ronald G. Crystal, James C. Hogg, Michael A. Province, Stephen I. Rennard, Duncan C. Thomas, Thomas Croxton, Weiniu Gan, Lisa Postow, John W. Walsh, Randel Plant, Delia Prieto, Daniel Cossette, Roxanne K. Kelly, Andre Williams, Ruthie Knowles, Carla Wilson, Jennifer Black-Shinn, Gregory Kinney, Peter J. Castaldi, Michael Cho, Dawn L. DeMeo, Marilyn G. Foreman, Nadia N. Hansel, Megan E. Hardin, Dennis Niewoehner, Tadashi Allen, COPDGene and ECLIPSE Investigators

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

Background: Chronic bronchitis (CB) is one of the classic phenotypes of COPD. The aims of our study were to investigate genetic variants associated with COPD subjects with CB relative to smokers with normal spirometry, and to assess for genetic differences between subjects with CB and without CB within the COPD population. Methods: We analyzed data from current and former smokers from three cohorts: the COPDGene Study; GenKOLS (Bergen, Norway); and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). CB was defined as having a cough productive of phlegm on most days for at least 3 consecutive months per year for at least 2 consecutive years. CB COPD cases were defined as having both CB and at least moderate COPD based on spirometry. Our primary analysis used smokers with normal spirometry as controls; secondary analysis was performed using COPD subjects without CB as controls. Genotyping was performed on Illumina platforms; results were summarized using fixed-effect meta-analysis. Results: For CB COPD relative to smoking controls, we identified a new genome-wide significant locus on chromosome 11p15.5 (rs34391416, OR = 1.93, P = 4.99 × 10-8) as well as significant associations of known COPD SNPs within FAM13A. In addition, a GWAS of CB relative to those without CB within COPD subjects showed suggestive evidence for association on 1q23.3 (rs114931935, OR = 1.88, P = 4.99 × 10-7). Conclusions: We found genome-wide significant associations with CB COPD on 4q22.1 (FAM13A) and 11p15.5 (EFCAB4A, CHID1 and AP2A2), and a locus associated with CB within COPD subjects on 1q23.3 (RPL31P11 and ATF6). This study provides further evidence that genetic variants may contribute to phenotypic heterogeneity of COPD. Trial registration: ClinicalTrials.gov NCT00608764, NCT00292552.

Original languageEnglish (US)
Article number113
JournalRespiratory research
Volume15
Issue number1
DOIs
StatePublished - Sep 21 2014

Bibliographical note

Publisher Copyright:
© 2014 Lee et al.; licensee BioMed Central Ltd.

Keywords

  • Chronic bronchitis
  • Chronic obstructive
  • Genome-wide association study
  • Pulmonary disease

Fingerprint

Dive into the research topics of 'Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this